Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00877890 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)
A Phase 3 study of Type 2 Diabetes Mellitus, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 254
- Enrollment target
- 20
- Study locations
NCT00877890: Completed Phase 3 study of Type 2 Diabetes Mellitus, sponsored by AstraZeneca.
NCT00877890 is a Phase 3 study of Type 2 Diabetes Mellitus that has completed, run by AstraZeneca. The registered enrollment target is 254 participants, below the 2,958-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00877890, a Phase 3 study of Type 2 Diabetes Mellitus, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 254 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications. The study will examine glycemic control (as measured by HbA1C), safety, and tolerability.
Primary Outcome
Change in HbA1c from baseline (Day 1) to Week 24 \[Week 24 - Baseline\].
Conditions Studied
Interventions
- DRUG exenatide once weekly
- DRUG exenatide twice daily
Study Locations (20)
California
- Research Site - Artesia
- Research Site - Concord
- Research Site - Encino
- Research Site - Greenbrae
- Research Site - La Mesa
- Research Site - Walnut Creek
Florida
- Research Site - DeLand
- Research Site - Hialeah
- Research Site - Miami
- Research Site - New Port Richey
- Research Site - Palm Harbor
Arizona
- Research Site - Mesa
- Research Site - Peoria
Indiana
- Research Site - Avon
- Research Site - Evansville
Kentucky
- Research Site - Lexington
- Research Site - Paducah
Alabama
- Research Site - Birmingham
Illinois
- Research Site - Chicago
Michigan
- Research Site - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-01 |
| Phase | Phase 3 |
What the finished NCT00877890 record still lists
NCT00877890 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, below the 2,958-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which exenatide once weekly is the first listed.
NCT00877890 names 20 study sites across 8 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00877890 about?
NCT00877890 is a clinical study titled "A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)". This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications. The study will examine glycemic control (as measured by HbA1C), safety, and tolera...
What is the current status of trial NCT00877890?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 254 participants. The study started on 2009-03. Estimated completion is 2010-01.
What conditions does trial NCT00877890 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT00877890?
The interventions under investigation include: exenatide once weekly (DRUG), exenatide twice daily (DRUG).
Who is sponsoring clinical trial NCT00877890?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00877890 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00877890's enrollment target sits among peer trials
254 31st of 130 higher than 100 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
RECRUITING · Phase 3
-
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
COMPLETED · Phase 3
-
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
COMPLETED · Phase 3
-
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia